The DOI matches its Crossref record.
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
Open accessAbstract
Background & aims Long-term ursodeoxycholic acid (UDCA) therapy slows the progression of primary biliary cirrhosis. This study examined the effect of UDCA therapy on survival free of liver transplantation in a large group of patients.Methods Data from three clinical trials were combined in which patients with primary biliary cirrhosis were randomly assigned to receive UDCA (n = 273) or placebo (n = 275). After 2 years, patients from French and Canadian studies received UDCA for up to 2 years. Patients from the American study remained on their assigned treatment for up to 4 years.Results Survival free of liver transplantation was significantly improved in the patients treated with UDCA compared with the patients originally assigned to placebo (P < 0.001; relative risk, 1.9; 95% confidence interval, 1.3-2.8). Subgroup analyses showed that survival free of liver transplantation was significantly improved in medium- and high-risk groups (serum bilirubin level, 1.4 to 3.5 or > 3.5 mg/dL; P < 0.0001 and P < 0.03, respectively) and histological stage IV subgroup (P < 0.01).Conclusions Long-term UDCA therapy improves survival free of liver transplantation in patients with moderate or severe disease. An effect in patients with mild disease is probably not found because they do not progress to end-stage disease in 4 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some studies with extended follow-up have also shown improved survival.(59,62,63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, patients with earlier histologic stage usually respond more favorably to UDCA than patients with advanced disease, although patients with advanced disease may benefit in survival or avoid liver transplantation with this therapy.(63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with ursodeoxycholic acid decreases the levels of the biochemical markers of cholestasis and extends the time to liver transplantation.4,5”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Research works printed but not linked: 7
- [2]2. Babbs C, Hunt LP, Haoubi NY, Smith A, Rowan BP, Warnes TW. sponse to ursodeoxycholic acid. Gut 1995;36:935-938. Type III procollagen peptide: a marker of disease activity and 15. Christensen E, Crowe JP, Doniach D, Popper H, Ranek L, Rode ´s prognosis in primary biliary cirrhosis. Lancet 1988;1:1021- J, Tygstrup N, Williams R. Clinical pattern and course of disease 1024. in primary biliary cirrhosis based on an analysis of 236 patients.
- [3]3. Poupon RE, Balkau B, Gue ´chot J, Heintzmann F. Predictive fac- Gastroenterology 1980;78:236-246. tors in ursodeoxycholic acid-treated patients: role of serum mark- 16.
- [4]4. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival ers of connective tissue. Hepatology 1994;19:635-640. of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:701-713.
- [5]5. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic Received June 20, 1996. Accepted March 14, 1997. factor in primary biliary cirrhosis. Gut 1979;20:137-140. Address requests for reprints to: Rene ´e E. Poupon, Dr. Sci., IN- 18.
- [6]6. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance SERM Unite ´21, 16, Avenue Paul-Vaillant-Couturier, 94807 Villejuif of clinical and histological features in asymptomatic and symp- Cedex, France. Fax: (33) 01-4726-9454. tomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7. The authors thank Anne-Marie Bonnand for her helpful discussion
- [7]7. Christensen E, Neuberger J, Crowe JP, Altman DG, Popper H, and Christine Gue ´mene ´for her expert technical assistance. Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R. Benefi- Presented, in part, at the 43rd Annual Meeting of the American cial effect of azathioprine and prediction of prognosis in primary Society for the Study of Liver Diseases, May 14-17, 1995, San biliary cirrhosis: final results of an international trial. Gastroenter- ology 1985;89:1084-1091.
- [8]8. Brunner of Brunner's Glands Johann Conrad Brunner (1653-1727) was born at Schaffhausen, Switzer- land, near the Rheinfall. He graduated from the university at Strasbourg, and later studied in Paris and then in England under Thomas Willis. He became a professor of anatomy at Heidelberg where he published his Disser- tatio inauguralis de glandulis duodeno intestino in 1687. Actually, Brunner's father-in-law J. J. Wepfer had previously described the glands of the duode- nal mucosa in 1679, but it was Brunner's inaugural dissertation that at- tracted attention, and hence the eponym. / 5E20$$0021 08-08-97 18:15:00 gasas WBS-Gastro
Cited by
Sorted by citations
Items 301–400 of 647
Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis
Angulo, P., El-Amin, O., Carpenter, H. A., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04675.x · Cited by 23
Self-citationUrsodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression
Paumgartner, G. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00243-5 · Cited by 24
PRIMARY BILIARY CIRRHOSIS, PRIMARY SCLEROSING CHOLANGITIS, AND AUTOIMMUNE CHOLANGITIS
Sherlock, S. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70098-2 · Cited by 23
Update on Primary Biliary Cirrhosis
Heathcote, J. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/989486 · Cited by 23
Neuberger, J. (2000) · Hepatology · doi:10.1002/hep.510310431 · Cited by 24
Roberts, S. B., Choi, W. J., Worobetz, L., Vincent, C., Flemming, J. A., Cheung, A., Qumosani, K. M., Swain, M. G., Grbic, D., Ko, H. H., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101168 · Cited by 23
Self-citationMinuk, G. Y., Iliant, V., Zhou, N., Kaita, K., Wong, S. G., Peretz, D., & Uhanova, J. (2017) · Liver International · doi:10.1111/liv.13644 · Cited by 22
Pharmacotherapy of cholestatic liver diseases
Paumgartner, G. (2010) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2010.00427.x · Cited by 22
Diagnosis and management of primary biliary cirrhosis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.979792 · Cited by 23
Self-citationTreatment of primary biliary cirrhosis
Poupon, R. Y., & Poupon, R. E. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0107 · Cited by 22
Self-citationLiver Transplantation in Primary Biliary Cirrhosis: Risk Assessment and 11-Year Follow-Up
Rust, C., Rau, H. G., Gerbes, A. L., Pape, G. R., Haller, M., Krämling, H.-J., Schildberg, F. W., Paumgartner, G., & Beuers, U. H. (2000) · Digestion · doi:10.1159/000007776 · Cited by 22
Management of pre–liver transplantation patient—Part 2
Sharma, P., & Rakela, J. L. (2005) · Liver Transplantation · doi:10.1002/lt.20379 · Cited by 22
Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)
Janmohamed, A., & Trivedi, P. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.002 · Cited by 21
Tauroursodeoxycholic acid mobilizes α‐PKC after uptake in human HepG2 hepatoma cells
Glasová, H., Berghaus, T. M., Kullak-Ublick, G. A., Paumgartner, G., & Beuers, U. H. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.01002.x · Cited by 21
Jopson, L., Newton, J. L., Palmer, J. M., Floudas, A., Isaacs, J. D., Qian, J., Wilkinson, J. S., Trenell, M. I., Blamire, A. M., Howel, D., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007985 · Cited by 20
Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid
Boberg, K. M., Wisløff, T. F., Kjøllesdal, K. S., Støvring, H., & Kristiansen, I. S. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12435 · Cited by 20
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Smith, T. M., & Befeler, A. S. (2007) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0021-z · Cited by 20
Update on pharmacotherapies for cholestatic liver disease
Ali, A. H., Tabibian, J. H., & Lindor, K. D. (2016) · Hepatology Communications · doi:10.1002/hep4.1013 · Cited by 21
Self-citationEmerging novel treatments for autoimmune liver diseases
Tanaka, A. (2019) · Hepatology Research · doi:10.1111/hepr.13347 · Cited by 19
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
Dohmen, K., Onohara, S.-Y., & Harada, S. (2021) · The Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.092 · Cited by 18
Primary biliary cirrhosis in Asians: Less common than in Europeans, but just as depressing
Farrell, G. C. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05379.x · Cited by 18
Liver Transplantation for Patients with Cholestatic Liver Diseases
Schöning, W., Schmeding, M., Ulmer, T. F., Andert, A., & Neumann, U. P. (2015) · Visceral Medicine · doi:10.1159/000431017 · Cited by 18
Kinzler, I., Haseroth, E., Hauser, C., & Rück, A. C. (2007) · Photochemical & Photobiological Sciences · doi:10.1039/b705919a · Cited by 17
Emerging drugs for the treatment of Primary Biliary Cholangitis
Ali, A. H., Tabibian, J. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1150999 · Cited by 18
Self-citationNew insights into autoimmune liver diseases
Kumagi, T., Alswat, K., Hirschfield, G. M., & Heathcote, J. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00366.x · Cited by 17
Benini, F., Pigozzi, M. G., Baisini, O., Romanini, L., Ahmed, H. A., Pozzi, A., Ricci, C., & Lanzini, A. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04733.x · Cited by 17
Primary biliary cirrhosis: From bench to bedside
Kouroumalis, E. (2015) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v6.i3.32 · Cited by 17
Angulo, P., & Lindor, K. D. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00089-5 · Cited by 17
Self-citationCarbone, M., Gerussi, A., Cardinale, V., Cazzagon, N., Cossiga, V., Lleò, A., Marrone, G., Marzioni, M., Moschetta, A., Muratori, L., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.002 · Cited by 18
Autoimmune liver disease for the non-specialist
Decock, S., McGee, P., & Hirschfield, G. M. (2009) · BMJ · doi:10.1136/bmj.b3305 · Cited by 16
Pereira, J. P., Rodrigues, A. M., Canhão, H. M., Saraiva, F., da Silva, J. A. P., & Fonseca, J. E. (2011) · Clinical Rheumatology · doi:10.1007/s10067-011-1879-y · Cited by 16
Levy, C., Bowlus, C. L., Carey, E. J., Crawford, J. M., Deane, K., Mayo, M. J., Kim, W. R., & Fried, M. W. (2018) · Hepatology Communications · doi:10.1002/hep4.1173 · Cited by 16
POTENTIAL NEW THERAPIES FOR ALCOHOLIC LIVER DISEASE
Mullen, K. D., & Dasarathy, S. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70046-5 · Cited by 16
Neuman, M. G., Cameron, R., Haber, J. A., Katz, G. G., & Blendis, L. M. (2002) · Liver International · doi:10.1046/j.0106-9543.2002.01640.x · Cited by 16
Untas, A., Boujut, É., Corpechot, C., Zenasni, F., Chazouillères, O., Jaury, P., Poupon, R. Y., du Vaure, C. B., & Sultan, S. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.07.003 · Cited by 16
Self-citationUrsodeoxycholic acid for primary biliary cirrhosis: lesson for the future?
Gluud, C. N., & Christensen, E. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00061-7 · Cited by 16
Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis
Torisu, Y., Nakano, M., Takano, K., Nakagawa, R., Saeki, C., Hokari, A., Ishikawa, T., Saruta, M., & Zeniya, M. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i1.57 · Cited by 15
Parés, A. R., Albillos, A., Andrade, R. J., Berenguer, M., Crespo, J., Romero‐Gómez, M., Vergara, M., Vendrell, B., & Gil, A. (2018) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2018.5665/2018 · Cited by 15
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Bartts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, E. R., & Lindor, K. D. (1999) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199906000-00019 · Cited by 15
Self-citationCurrent concepts in the pathogenesis of primary biliary cirrhosis
Charatcharoenwitthaya, P., & Lindor, K. D. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32061-7 · Cited by 15
Self-citationPrimary biliary cirrhosis and liver transplantation
Akamatsu (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.2.66 · Cited by 17
Current and promising therapy for primary biliary cholangitis
Gossard, A. A., & Lindor, K. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601701 · Cited by 15
Self-citationUrsodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines
Tsochatzis, E. A., Gurusamy, K. S., Gluud, C. N., & Burroughs, A. K. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.09.015 · Cited by 15
The Inconvenient Truth of Primary Biliary Cholangitis/Autoimmune Hepatitis Overlap Syndrome
Hussain, N., & Trivedi, P. J. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.007 · Cited by 16
Fang, Y., Lv, D.-X., Jia, W. P., Li, ., Deng, Y., Wang, Y., Yu, M., & Wang, G. (2014) · Medicine · doi:10.1097/md.0000000000000104 · Cited by 14
Improving prognosis in primary biliary cholangitis – Therapeutic options and strategy
Harms, M. H., van Buuren, H. R., & van der Meer, A. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.004 · Cited by 14
Dhillon, A., & Steadman, R. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2787-6.00005-x · Cited by 14
Gentilucci, U. V., Rosina, F., Pace-Palitti, V., Sacco, R., Pellicelli, A. M., Chessa, L., Vincentis, A. D., Barlattani, M., Barlattani, A., Feletti, V., et al. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1669702 · Cited by 14
The management of autoimmunity in patients with cholestatic liver diseases
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1095088 · Cited by 14
Self-citationLee, Y.-M., & Kaplan, M. M. (1999) · Current Gastroenterology Reports · doi:10.1007/s11894-999-0085-4 · Cited by 14
Treatment of primary biliary cirrhosis
Szalay, F. (2001) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(01)00055-9 · Cited by 14
Beck, I. T. (2001) · PubMed · Cited by 14
Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis
Levy, C., & Lindor, K. D. (2003) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-003-0010-0 · Cited by 13
Self-citationPredictive Scores in Primary Biliary Cirrhosis
Weinmann, A., Sattler, T., Unold, H.-P., Grambihler, A., Teufel, A., Koch, S., Schuchmann, M., Biesterfeld, S., Wörns, M., Galle, P. R., et al. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000176 · Cited by 13
Charatcharoenwitthaya, P., Talwalkar, J. A., Angulo, P., Gossard, A. A., Keach, J. C., Petz, J. L., Jorgensen, R. A., & Lindor, K. D. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0744-1 · Cited by 13
Self-citationAn Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis
Burman, B. E., Jhaveri, M. A., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.06.005 · Cited by 13
Role of circulating soluble CD40 as an apoptotic marker in liver disease
Schmilovitz‐Weiss, H., Belinki, A., Pappo, O., Sulkes, J., Melzer, E., Kaganovsky, E., Kfir, B., Tur‐Kaspa, R., Klein, T., & Ben‐Ari, Z. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000018802.95600.25 · Cited by 13
Cirrosis biliar primaria: experiencia de trece años en dos centros de referencia
Valera, J. M., Gladys Smok, S., Jaime Poniachik, T., Danny Oksenberg, R., Guillermo Silva, P., Ferrario, M., Erwin Buckel, G., & Javier Brahm, B. (2006) · Revista médica de Chile · doi:10.4067/s0034-98872006000400010 · Cited by 13
Bateson, M. C., & Gedling, P. (1998) · Postgraduate Medical Journal · doi:10.1136/pgmj.74.874.482 · Cited by 13
Neuberger, J. (2002) · Medicine · doi:10.1383/medc.30.12.57.28526 · Cited by 13
Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis
Heathcote, J. (1998) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1998.tb00667.x · Cited by 13
Wiegand, J., Franke, A., Müller, T., Stein, K., Bantel, H., Günther, R., Denk, G., Reuken, P. A., Schattenberg, J. M., Naumann, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2382-7720 · Cited by 12
Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
Zhu, G., Huang, S., Huang, G., Wang, L., Lin, Y.-Q., Wu, Y.-M., Shi, K., Wang, J., Zhou, Z., Braddock, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4528 · Cited by 12
Jung, H. E., Jang, J. Y., Jeong, S. W., Kim, J. N., Jang, H. Y., Cho, Y. J., Woo, S. A., Lee, S. H., Kim, S. G., Cha, S., et al. (2012) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2012.18.4.375 · Cited by 12
Matsumoto, K., Hirohara, J., Takeuchi, A., Miura, R., Asaoka, Y., Nakano, T., & Tanaka, A. (2023) · Hepatology Research · doi:10.1111/hepr.13931 · Cited by 12
Baruch, Y., Assy, N., Weisbruch, F., Reisner, S. A., Rinkevich, D., Enat, R., Blendis, L. M., & Bomzon, A. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00506-7 · Cited by 12
Khanna, A., Jopson, L., Howel, D., Bryant, A., Blamire, A. M., Newton, J. L., Wilkinson, J. S., Steel, A. J., Bainbridge, J., Stefanetti, R. J., et al. (2018) · Efficacy and Mechanism Evaluation · doi:10.3310/eme05020 · Cited by 12
Ni, P., Men, R., Shen, M., Wang, T., Huang, C., Fan, X., & Yang, L. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/7396870 · Cited by 12
Purucker, E. A. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00096-4 · Cited by 12
Rossi, M., Mennini, G., Lai, Q., Corradini, S. G., Drudi, F. M., Pugliese, F. R., & Berloco, P. B. (2007) · Journal of Ultrasound · doi:10.1016/j.jus.2007.02.006 · Cited by 12
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Self-citationManagement of primary biliary cirrhosis resistant to ursodeoxycholic acid therapy
Poupon, R. Y. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80438-9 · Cited by 12
Self-citationCurrent Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases
Durazzo, M., Ferro, A., Navarro‐Tableros, V., Gaido, A., Fornengo, P., Altruda, F., Romagnoli, R., Moestrup, S. K., Calvo, P. L., & Fagoonee, S. (2025) · Biomolecules · doi:10.3390/biom15010121 · Cited by 11
Current Treatment Options for Primary Biliary Cholangitis
Wong, K. A., Bahar, R., Liu, C. H., & Bowlus, C. L. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.003 · Cited by 11
Li, X., Liao, M., Pan, Q., Xie, Q., Yang, H., Peng, Y. H., Li, Q., Qu, J., & Chai, J. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001785 · Cited by 11
Hosonuma, K., Sato, K., Yanagisawa, M., Kakizaki, S., Takagi, H., Hirato, J., & Mori, M. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/168012 · Cited by 11
Management of primary biliary cirrhosis
Levy, C., & Lindor, K. D. (2003) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-003-0051-4 · Cited by 11
Self-citationShaw, A. S., Ryan, S. M., Beese, R. C., Norris, S., Bowles, M. J., Rela, M., & Sidhu, P. S. (2002) · Imaging · doi:10.1259/img.14.4.140314 · Cited by 11
Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management.
Schreibman, I. R., & Regev, A. (2006) · PubMed Central · Cited by 10
PREDICTIVE MODELS OF NATURAL HISTORY IN PRIMARY BILIARY CIRRHOSIS
Kim, W. R., & Dickson, E. R. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70010-6 · Cited by 10
Self-citationHeathcote, E. J. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70009-x · Cited by 10
Self-citationPrimary Sclerosing Cholangitis
Stiehl, A., Benz, C., & Sauer, P. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/983681 · Cited by 10
Jopson, L., Khanna, A., Peterson, P., Rudell, E., Corrigan, M., & Jones, D. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5074-8 · Cited by 9
Treatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9
Parés, A. R. (2015) · Digestive Diseases · doi:10.1159/000440761 · Cited by 9
Silveira, M. G. (2014) · Clinical gastroenterology · doi:10.1007/978-1-4939-1013-7_3 · Cited by 9
Oxidative and Nitrosative Stress in Chronic Cholestasis
Grattagliano, I., Oliveira, P. J., Vergani, L., & Portincasa, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804274-8.00017-5 · Cited by 9
BILE ACID ABNORMALITIES IN CHOLESTATIC LIVER DISEASES
Salen, G., & BATTA, A. K. (1999) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70049-2 · Cited by 9
Asciutti, S., Castellani, D., Nardi, E., Morelli, O., Clementi, M., Chistolini, F., Gentili, G., Setchell, K. D. R., O’Connell, N. C., Pellicciari, R., et al. (2009) · PubMed · Cited by 9
Cheung, K. S., Seto, W., Fung, J., Mak, L., Lai, C., & Yuen, M. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i44.7863 · Cited by 9
Management of pre-liver transplantation patients—Part 1
Sharma, P., & Rakela, J. L. (2005) · Liver Transplantation · doi:10.1002/lt.20353 · Cited by 9
Medical and economic impact of autoimmune hepatitis
Talwalkar, J. A., & Kim, W. R. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00030-2 · Cited by 10
Bar‐Dayan, Y., Gershwin, M. E., Levi, Y., Amital, H., & Shoenfeld, Y. (1998) · Immunologic Research · doi:10.1007/bf02788754 · Cited by 9
Primary biliary cirrhosis: specific treatment
Carithers, R. L. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00103-x · Cited by 9
Heathcote, J. (2004) · Wiley eBooks · doi:10.1002/9780470987025.ch28 · Cited by 9
Primary biliary cholangitis: current insights and novel therapies
Granito, A., Παππάς, Γ., Napoli, L., Stefanini, B., Tirotta, D., & Muratori, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2672493 · Cited by 8
HEPATOLOGY IN THE NEW MILLENNIUM
Ramrakhiani, S., & Bacon, B. R. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70277-7 · Cited by 8
Prim�r bili�re Leberzirrhose und Overlap-Syndrome
Strassburg, C. P., & Manns, M. P. (2004) · Der Internist · doi:10.1007/s00108-003-1127-x · Cited by 8
Treeprasertsuk, S., Silachamroon, U., Krudsood, S., Huntrup, A., Suwannakudt, P., Vannaphan, S., & Wilairatana, P. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06007.x · Cited by 8
The Therapeutic Role of Ursodeoxycholic Acid in Digestive Diseases
Gamboa, A. M., Tian, C., Massaad, J., Reshamwala, P. A., & Cai, Q. (2011) · Cited by 8
Metadata
- Authors
- Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E.
- Affiliations
- Mayo Clinic (US)
- Inserm (FR)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1997-09
- Volume
- 113
- Issue
- 3
- Pages
- 884-890
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2071394537
- Semantic Scholar
- b05e12d331fd48ec432f894f09036aaff9a53c62
- Cited by
- 648
- References
- 0
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 15 · 2023: 9 · 2022: 5 · 2021: 15 · 2020: 21 · 2019: 23 · 2018: 27 · 2017: 26 · 2016: 12 · 2015: 24 · 2014: 26 · 2013: 13 · 2012: 17
- FWCI
- 21.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- ursodeoxycholic acid, primary biliary cirrhosis, liver transplantation, disease severity, serum bilirubin, subgroup analysis, treatment efficacy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cause of Death, Female, Forecasting, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Postoperative Care, Severity of Illness Index, Ursodeoxycholic Acid, Survival Analysis, Liver Transplantation, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
